Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Total Debt

Short-term and long-term borrowings combined.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt falls 29.7% from a year ago

Total debt stood at $61.89M at the end of Q2 FY2026, down 29.7% from a year earlier and down 14.5% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.

Context

  • Total debt amounted to 5.1% of total assets at the end of Q2 FY2026, down 1.7 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$61.89M-14.5% QoQ
Last fiscal yearDec 2025
$77.97M-28.1% YoY
Year agoJun 2025
$88.08M-29.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.7%——
1 year-28.1%——
3-year CAGR+15.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
77.97M USD
Year-over-year change
-28.1%
4-year CAGR
+61.4%

Total Debt vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's Jun 2026 total debt of $61.89M is the highest of the 4 companies compared; the peer median is $30.66M.
  • Its year-over-year change of -29.7% is the 3rd highest of 4, against a peer median of -10.3%.
  • Total debt amounts to 5.1% of total assets for RXRX, versus a peer median of 3.2%.
RXRX Competitors Peer median
Total Debt for RXRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RXRXRecursion Pharmaceuticals, Inc.Jun 2026$61.89M -29.7%+15.2%5.1%
MAZEMaze Therapeutics, Inc.Mar 2026$61.22M +137.1%-10.1%14.6%
RLAYRelay Therapeutics, Inc.Jun 2026$30.66M -10.3%-17.5%3.2%
DNLIDenali Therapeutics Inc.Jun 2026$27.51M -40.9%-15.2%2.4%
Peer median (excluding RXRX) $30.66M-10.3%-15.2%3.2%

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents285.12M549.91M391.57M594.35M743.29M
Short-term Investments231.45M0000
Net Receivables9.09M2.75M3.09M49.17M24.65M
Inventory00000
Other Current Assets9.07M17.15M43.48M70.75M33.16M
Total Current Assets534.72M569.81M438.14M714.27M812.85M
Property, Plant & Equipment (Net)64.73M121.45M120.17M233.21M169.48M
Goodwill801K801K52.06M148.87M162.16M
Intangible Assets1.39M1.31M36.44M335.86M309.9M
Long-term Investments0005.63M0
Tax Assets0001.93M957K
Other Non-current Assets8.72M7.92M6.89M8.83M18.79M
Total Non-current Assets75.63M131.47M215.56M734.33M661.29M
Total Assets610.35M701.29M653.7M1.45B1.47B
Account Payables2.82M4.59M3.95M21.61M18.12M
Short-term Debt90K97K41K8.43M9.09M
Tax Payables00000
Deferred Revenue10M56.73M36.43M61.77M37.61M
Other Current Liabilities11.74M20.43M23.75M50.85M31.77M
Total Current Liabilities46.66M100.27M93.17M187.47M147.71M
Long-term Debt633K536K1.1M19.02M9.56M
Deferred Tax Liabilities001.34M16.58M23.26M
Deferred Revenue (Non-current)6.67M70.26M51.24M118.77M114.01M
Other Non-current Liabilities4.11M004.73M2.08M
Total Non-current Liabilities20.75M115.22M97.09M226.34M195.56M
Total Liabilities67.41M215.48M190.26M413.82M343.27M
Common Stock2K2K2K4K5K
Retained Earnings(400.08M)(639.56M)(967.62M)(1.43B)(2.08B)
Accumulated OCI(126K)00(7.64M)36.72M
Other Stockholders Equity00000
Minority Interest00000
Total Equity542.94M485.81M463.44M1.03B1.13B
Total Debt11.48M51.01M50.67M108.49M77.97M
Net Debt(273.64M)(498.91M)(340.89M)(485.86M)(665.33M)

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.